NSAIDs
We recommend nonsteroidal anti-inflammatory drugs (NSAIDs; oral or topical) or Tramadol for patients with symptomatic osteoarthritis of the knee.
Rationale
This recommendation included studies of both selective (cyclo-oxygenase-2, COX-2 inhibitors) and non-selective NSAIDs. The endorsement for NSAIDs was based on 202 favorable outcomes from 19 studies comparing either the selective, non-selective or topical analgesics to placebo. Twelve studies were of selective NSAIDs, four were of non-selective oral NSAIDs, and six were of topical NSAIDs. (Three studies compared multiple types of analgesics to placebo.) Three were high-strength studies, 14 were moderate, and two were of low-strength. The moderate and low strength studies were included because they examined different outcomes than the high strength articles. Out of 202 total outcomes, 171 were statistically significant in favor of the experimental group. Fifteen outcomes were above the MCII threshold and 63 outcomes were possibly clinically significant. The remaining outcomes were neither statistically nor clinically significant.
Two high- and three moderate- strength studies examining the various outcome measures in this recommendation compared tramadol to placebo. They included outcome measurements with follow up periods that ranged from 8 to 13 weeks in duration. Ten of 14 outcomes were statistically significant in favor of the treatment group. Two statistically significant outcomes (WOMAC pain and stiffness subscale scores) were possibly clinically significant and the other eight outcomes could not be evaluated. Fishman et al.95 did not find any statistically significant improvements in pain efficacy between tramadol contramid doses of 100mg, 200mg and 300mg. Beaulieu et al.96 found similar treatment effects in tramadol and diclofenac in using WOMAC pain, stiffness and function subscale scales.
The recommendation on acetaminophen was downgraded from level B (i.e. Moderate) in the 2008 edition of the guideline to inconclusive in our current guideline. As opposed to the selection criteria previously used, our current systematic review examined acetaminophen separately and found only one relevant study that tested it against placebo (Miceli-Richard et al.97). Their study found no statistical significance or minimum clinically important improvement to patients compared to placebo. In addition, their findings and the previous clinical guideline were based on the usage of a maximum of 4000 mg of acetaminophen per day, and there has been a recent change to a dosage not to exceed 3000 mg per day; see: FDA Acetaminophen Dosage Announcement.
The work group realizes that many practitioners prefer to start with acetaminophen prior to NSAIDs due to the side effect profile of NSAIDs. However, we found it unreasonable to recommend a treatment that does not show benefit over placebo.
Our literature review found no relevant studies meeting our inclusion criteria on opioids or pain patches for the treatment of knee osteoarthritis.
Two high- and three moderate- strength studies examining the various outcome measures in this recommendation compared tramadol to placebo. They included outcome measurements with follow up periods that ranged from 8 to 13 weeks in duration. Ten of 14 outcomes were statistically significant in favor of the treatment group. Two statistically significant outcomes (WOMAC pain and stiffness subscale scores) were possibly clinically significant and the other eight outcomes could not be evaluated. Fishman et al.95 did not find any statistically significant improvements in pain efficacy between tramadol contramid doses of 100mg, 200mg and 300mg. Beaulieu et al.96 found similar treatment effects in tramadol and diclofenac in using WOMAC pain, stiffness and function subscale scales.
The recommendation on acetaminophen was downgraded from level B (i.e. Moderate) in the 2008 edition of the guideline to inconclusive in our current guideline. As opposed to the selection criteria previously used, our current systematic review examined acetaminophen separately and found only one relevant study that tested it against placebo (Miceli-Richard et al.97). Their study found no statistical significance or minimum clinically important improvement to patients compared to placebo. In addition, their findings and the previous clinical guideline were based on the usage of a maximum of 4000 mg of acetaminophen per day, and there has been a recent change to a dosage not to exceed 3000 mg per day; see: FDA Acetaminophen Dosage Announcement.
The work group realizes that many practitioners prefer to start with acetaminophen prior to NSAIDs due to the side effect profile of NSAIDs. However, we found it unreasonable to recommend a treatment that does not show benefit over placebo.
Our literature review found no relevant studies meeting our inclusion criteria on opioids or pain patches for the treatment of knee osteoarthritis.
- (100) Ottillinger B, Gomor B, Michel BA, Pavelka K, Beck W, Elsasser U. Efficacy and safety of eltenac gel in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 2001;9(3):273-280. PM:11300751
- (101) Rother M, Lavins BJ, Kneer W, Lehnhardt K, Seidel EJ, Mazgareanu S. Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial. Ann Rheum Dis 2007;66(9):1178-1183. PM:17363401
- (95) Fishman RL, Kistler CJ, Ellerbusch MT et al. Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once-daily tramadol (Tramadol Contramid OAD). J Opioid Manag 2007;3(5):273-280. PM:18181382
- (96) Beaulieu AD, Peloso PM, Haraoui B et al. Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Res Manag 2008;13(2):103-110. PM:18443672
- (97) Miceli-Richard C, Le BM, Schmidely N, Dougados M. Paracetamol in osteoarthritis of the knee. Ann Rheum Dis 2004;63(8):923-930. PM:15249319
- (98) Schnitzer TJ, Weaver AL, Polis AB, Petruschke RA, Geba GP. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies. J Rheumatol 2005;32(6):1093-1105. PM:15940774
- (99) Evcik D, Maralcan G, Kuru I. The efficacy of intra-articular tenoxicam in the treatment of knee osteoarthritis. Pain Clinic 2003;15(4):405-408.
- Astorga PG,Baigun S,Galvao de FJ,Gomes de FG. Efficacy and tolerability comparison of etodolac and Piroxicam in the treatment of patients with osteoarthritis of the knee. Curr Med Res Opin 1991;12(6):401-412.
- Ayral X,Mackillop N,Genant HK,Kirkpatrick J,Beaulieu A,Pippingskiold P,Will RK,Alava S,Dougados M. Arthroscopic evaluation of potential structure-modifying drug in osteoarthritis of the knee. A multicenter, randomized, double-blind comparison of Tenidap sodium versus Piroxicam. Osteoarthritis Cartilage 2003;11(3):198-207.
- Babul N,Noveck R,Chipman H,Roth SH,Gana T,Albert K. Efficacy and safety of extended-release, once-daily Tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage 2004;28(1):59-71.
- Baer PA,Thomas LM,Shainhouse Z. Treatment of osteoarthritis of the knee with a topical Diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886]. BMC Musculoskelet Disord 2005;6:44.
- Barthel HR,Haselwood D,Longley S,Gold MS,Altman RD. Randomized controlled trial of Diclofenac sodium gel in knee osteoarthritis. Semin Arthritis Rheum 2009;39(3):203-212.
- Bellamy N,Buchanan WW,Chalmers A,Ford PM,Kean WF,Kraag GR,Gerecz-Simon E,Campbell J. A multicenter study of tenoxicam and Diclofenac in patients with osteoarthritis of the knee. J Rheumatol 1993;20(6):999-1004.
- Bookman AA,Williams KS,Shainhouse JZ. Effect of a topical Diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ 2004;171(4):333-338.
- Bradley JD,Brandt KD,Katz BP,Kalasinski LA,Ryan SI. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and Acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991;325(2):87-91.
- Chubick AJ,Worley WE,Berman RS,Dobrinska MR. A double-blind multicenter study of sulindac once daily versus sulindac twice daily in osteoarthritis of the knee. CURR THER RES , CLIN EXP 1987;41:692-705.
- Dick WC,Bulstra S,Schardijn GH,Feenstra RM. Safety and efficacy of etodolac compared with Piroxicam in patients with degenerative joint disease of the knee. Clin Ther 1992;14(4):517-526.
- Ehrich EW,Schnitzer TJ,McIlwain H,Levy R,Wolfe F,Weisman M,Zeng Q,Morrison B,Bolognese J,Seidenberg B,Gertz BJ. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of Rofecoxib . Rofecoxib Osteoarthritis Pilot Study Group. J Rheumatol 1999;26(11):2438-2447.
- Fleischmann R,Sheldon E,Maldonado-Cocco J,Dutta D,Yu S,Sloan VS. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and Celecoxib . Clin Rheumatol 2006;25(1):42-53.
- Fleischmann RM,Caldwell JR,Roth SH,Tesser JRP,Olson W,Kamin M. Tramadol for the treatment of joint pain associated with osteoarthritis: A randomized, double-blind, placebo-controlled trial. Current Therapeutic Research, Clinical & Experimental 2001;62:113-128.
- Gibofsky A,Williams GW,McKenna F,Fort JG. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum 2003;48(11):3102-3111.
- Gottesdiener K,Schnitzer T,Fisher C,Bockow B,Markenson J,Ko A,DeTora L,Curtis S,Geissler L,Gertz BJ. Results of a randomized, dose-ranging trial of Etoricoxib in patients with osteoarthritis. Rheumatology (Oxford) 2002;41(9):1052-1061.
- Herrera JA,Millan A,Ramos R,Fuentes P,Gonzalez M. Evaluation of the effectiveness and tolerability of controlled-release Diclofenac-potassium versus immediate-release Diclofenac-potassium in the treatment of knee osteoarthritis. Current Therapeutic Research Clinical and Experimental 2007;68:82-93.
- Karbowski A. Double-blind, parallel comparison of etodolac and indomethacin in patients with osteoarthritis of the knee. Curr Med Res Opin 1991;12(5):309-317.
- Kogstad O. Double blind crossover trial of Piroxicam and Naproxen in the treatment of osteoarthritis of hip and knee. Br J Clin Pract 1981;35(1):45-50.
- Lehmann R,Brzosko M,Kopsa P,Nischik R,Kreisse A,Thurston H,Litschig S,Sloan VS. Efficacy and tolerability of Lumiracoxib 100mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study versus placebo and Celecoxib . Curr Med Res Opin 2005;21(4):517-526.
- Liang TH,Hsu PN. Double-blind, randomised, comparative trial of etodolac SR versus Diclofenac in the treatment of osteoarthritis of the knee. Curr Med Res Opin 2003;19(4):336-341.
- Lohmander LS,McKeith D,Svensson O,Malmenas M,Bolin L,Kalla A,Genti G,Szechinski J,Ramos-Remus C. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus Naproxen in osteoarthritis. Ann Rheum Dis 2005;64(3):449-456.
- Lucker PW,Pawlowski C,Friedrich I,Faiella F,Magni E. Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee. Eur J Rheumatol Inflamm 1994;14(2):29-38.
- Luyten FP,Geusens P,Malaise M,De CL,Westhovens R,Raeman F,Vander MD,Mathy L,Hauzeur JP,De KF,Van den Bosch F. A prospective randomised multicentre study comparing continuous and intermittent treatment with Celecoxib in patients with osteoarthritis of the knee or hip. Ann Rheum Dis 2007;66(1):99-106.
- Queiros MV. Piroxicam and oxaprozin: A crossover comparison in the management of osteoarthritis. Curr Ther Res Clin Exp 1990;47:466-474.
- Roth SH,Shainhouse JZ. Efficacy and safety of a topical Diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med 2004;164(18):2017-2023.
- Schnitzer TJ, Kivitz A, Frayssinet H, Duquesroix B. Efficacy and safety of Naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study. Osteoarthritis Cartilage 2010;18(5):629-639.
- Schnitzer TJ,Kamin M,Olson WH. Tramadol allows reduction of Naproxen dose among patients with Naproxen-responsive osteoarthritis pain: a randomized, double-blind, placebo-controlled study. Arthritis Rheum 1999;42(7):1370-1377.
- Schnitzer TJ,Tesser JR,Cooper KM,Altman RD. A 4-week randomized study of Acetaminophen extended-release versus Rofecoxib in knee osteoarthritis. Osteoarthritis Cartilage 2009;17(1):1-7.
- Tannenbaum H,Berenbaum F,Reginster JY,Zacher J,Robinson J,Poor G,Bliddal H,Uebelhart D,Adami S,Navarro F,Lee A,Moore A,Gimona A. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and Celecoxib . Ann Rheum Dis 2004;63(11):1419-1426.
- Tyson VC,Glynne A. A comparative study of Benoxaprofen and ibuprofen in osteoarthritis in general practice. J Rheumatol Suppl 1980;6:132-138.
- Williams GW,Ettlinger RE,Ruderman EM,Hubbard RC,Lonien ME,Yu SS,Zhao W,Geis GS. Treatment of osteoarthritis with a once-daily dosing regimen of Celecoxib : a randomized, controlled trial. J Clin Rheumatol 2000;6(2):65-74.
- Williams GW,Hubbard RC,Yu SS,Zhao W,Geis GS. Comparison of once-daily and twice-daily administration of Celecoxib for the treatment of osteoarthritis of the knee. Clin Ther 2001;23(2):213-227.